Sienna Biopharmaceuticals, Inc. a clinical-stage biotechnology company, announced positive topline results from its pivotal trial of SNA-001 in conjunction with an 810 nanometers diode laser, involving 65 patients. SNA-001, a topical pre-treatment to standard laser hair removal, was studied in women and men with white, gray, blonde, light red, and light brown hair. The data showed SNA-001 met the primary endpoint of non-inferiority in hair…